Screener / SEC EDGAR /CIK 0001818331 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Health Services

GeneDx Holdings Corp. WGS

Unless otherwise stated in this Annual Report or the context otherwise requires, references to: • “we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to GeneDx Holdings and its consolidated subsidiaries. 10-K, Item 1

Headquarters
Stamford, CT
CEO
Katherine Stueland
Next results
around Jan 11, 2027
Compare with peers Embed

WGS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 40.0%, above 88% of 154 peers (their median 10.4%) REVENUE GROWTH 40.0% · above 88% Gross margin: 68.7%, above 64% of 107 peers (their median 63.4%) GROSS MARGIN 68.7% · above 64% Operating margin: -21.6%, above 17% of 138 peers (their median 10.2%) OPERATING MARGIN -21.6% · above 17% Net margin: -24.1%, above 16% of 153 peers (their median 6.8%) NET MARGIN -24.1% · above 16% FCF margin: -22.0%, above 13% of 144 peers (their median 10.1%) FCF MARGIN -22.0% · above 13%
WGS Peer median Below the median

What changed

20 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 23, 2026 against Feb 20, 2025.

Risk factors
20 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Receivables growing faster than revenue
Receivables +97.6% ($37.6M to $74.4M) vs revenue +40.0% ($305.4M to $427.5M), +57.7 pts apart
10-K · XBRL
Critical audit matters changed
New this year: Measurement of diagnostic test revenue billed to third-party insurance payors (“During the year ended December 31, 2025, the Company recognized diagnostic test revenue billed to third-party insurance payors of $345 million. As discussed in Note 2 to the consolidated financial statements, the Company accepts payments from third-party insurance payors that are less than the contr”); Valuation of developed technology from the Fabric Genomics acquisition (“As discussed in Note 3 to the consolidated financial statements, during the year ended December 31, 2025, the Company completed the acquisition of Fabric Genomics, Inc. for total consideration of $36.5 million. The transaction was accounted for under the acquisition method of accounting whereby the ”)
10-K · XBRL
Material weakness in internal control
“Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2025, the end of the period covered by this Annual Report on Form 10-K, due to the material weakness in internal control over information technology general controls, or ITGCs, as described below.”
10-K · XBRL
Accounting checks
8 other checks clear, 3 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
2 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

3facts worth reading about the other 8 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +97.6% ($37.6M to $74.4M) vs revenue +40.0% ($305.4M to $427.5M), +57.7 pts apart
  • Critical audit matters changed
    New this year: Measurement of diagnostic test revenue billed to third-party insurance payors (“During the year ended December 31, 2025, the Company recognized diagnostic test revenue billed to third-party insurance payors of $345 million. As discussed in Note 2 to the consolidated financial statements, the Company accepts payments from third-party insurance payors that are less than the contr”); Valuation of developed technology from the Fabric Genomics acquisition (“As discussed in Note 3 to the consolidated financial statements, during the year ended December 31, 2025, the Company completed the acquisition of Fabric Genomics, Inc. for total consideration of $36.5 million. The transaction was accounted for under the acquisition method of accounting whereby the ”)
  • Material weakness in internal control
    “Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2025, the end of the period covered by this Annual Report on Form 10-K, due to the material weakness in internal control over information technology general controls, or ITGCs, as described below.”
  • Cash from operations $33.3M vs net income −$21.0M (FY ending Dec 31, 2025)
7 more checks with nothing to note
  • Inventory +31.0% ($10.7M to $14.0M) vs revenue +40.0% ($305.4M to $427.5M), -9.0 pts apart
  • Same auditor in both 10-Ks: ERNST & YOUNG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

20 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 20 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Furthermore, under the Tax Cuts and Jobs Act, NOLs generated in taxable years beginning after December 31, 2017 may offset only up to 80% of current-year taxable income and generally may not be carried back to prior years. State tax laws may impose similar or additional restrictions, and in certain jurisdictions the use of NOLs may be…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    On April 29, 2024, the FDA published a final rule on LDTs, in which the FDA outlined its plans to end enforcement discretion for many LDTs in five stages over a four-year period. In response, multiple lawsuits were filed challenging the FDA’s authority to regulate LDTs as medical devices under the Federal Food, Drug, and Cosmetic Act…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    A breakthrough device designation by the FDA, even though granted, may not lead to a faster development, regulatory review or authorization, nor a designation increase the likelihood that any of our product candidates will receive regulatory authorization in the United States. In October 2025, we received Breakthrough Device Designation…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious internal or external human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$234.7M$202.6M$305.4M$427.5M
Net income−$549.0M−$175.8M−$52.3M−$21.0M
Operating cash flow−$319.2M−$180.1M−$28.5M$33.3M
Free cash flow−$326.3M−$185.4M−$34.0M$14.3M

Revenue, FY2019 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$427.5M ▲ 40.0% in FY2025

FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

GeneDx Holdings Corp., Stamford, CT · from the 10-K filed Feb 23, 2026

Unless otherwise stated in this Annual Report or the context otherwise requires, references to: • “we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to GeneDx Holdings and its consolidated subsidiaries. The Company’s Class A common stock and public warrants are listed on the Nasdaq Global Select Market under the symbols “WGS” and “WGSWW,” respectively. At GeneDx, our mission is to empower everyone to live their healthiest life through genomics.

Headquarters
Stamford, CT
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 9, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WGS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.